
Maria Albanese

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4843532/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Orexinergic System Dysregulation, Sleep Impairment, and Cognitive Decline in Alzheimer Disease. JAMA Neurology, 2014, 71, 1498.	4.5	262
2	Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). Journal of Headache and Pain, 2021, 22, 35.	2.5	82
3	Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction. Haematologica, 2020, 105, 2056-2070.	1.7	70
4	No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology, 2017, 88, 1144-1152.	1.5	57
5	Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study. Sleep Medicine, 2016, 21, 140-144.	0.8	55
6	Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression. Journal of Neuroinflammation, 2016, 13, 36.	3.1	54
7	Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). Journal of Headache and Pain, 2022, 23, 46.	2.5	46
8	Heart rate variability in untreated newly diagnosed temporal lobe epilepsy: Evidence for ictal sympathetic dysregulation. Epilepsia, 2016, 57, 418-426.	2.6	45
9	Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3â€month observational, longitudinal, cohort, multicenter, Italian realâ€life study. European Journal of Neurology, 2022, 29, 1198-1208.	1.7	43
10	Increased cortical excitability after selective REM sleep deprivation in healthy humans: A transcranial magnetic stimulation study. Sleep Medicine, 2013, 14, 288-292.	0.8	42
11	<scp>CSF</scp> betaâ€amyloid levels are altered in narcolepsy: a link with the inflammatory hypothesis?. Journal of Sleep Research, 2014, 23, 420-424.	1.7	37
12	Sleep disorders in myotonic dystrophy type 2: a controlled polysomnographic study and selfâ€reported questionnaires. European Journal of Neurology, 2014, 21, 929-934.	1.7	37
13	Persistent post-traumatic headache: a migrainous loop or not? The clinical evidence. Journal of Headache and Pain, 2020, 21, 55.	2.5	37
14	Medication overuse and drug addiction: a narrative review from addiction perspective. Journal of Headache and Pain, 2021, 22, 32.	2.5	36
15	Nocturnal frontal lobe epilepsy with paroxysmal arousals due to CHRNA2 loss of function. Neurology, 2015, 84, 1520-1528.	1.5	32
16	Olfactory Dysfunction, Headache, and Mental Clouding in Adults with Long-COVID-19: What Is the Link between Cognition and Olfaction? A Cross-Sectional Study. Brain Sciences, 2022, 12, 154.	1.1	31
17	Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinson's disease. Journal of Neurology, 2019, 266, 636-641.	1.8	28
18	Cerebrospinal-fluid orexin levels and daytime somnolence in frontotemporal dementia. Journal of Neurology, 2014, 261, 1832-1836.	1.8	25

MARIA ALBANESE

#	Article	IF	CITATIONS
19	Modulation of monocytes by bioactive lipid anandamide in multiple sclerosis involves distinct Toll-like receptors. Pharmacological Research, 2016, 113, 313-319.	3.1	22
20	Sleep disorders in spinal and bulbar muscular atrophy (Kennedy's disease): a controlled polysomnographic and self-reported questionnaires study. Journal of Neurology, 2014, 261, 889-893.	1.8	21
21	Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients. Pharmaceuticals, 2021, 14, 336.	1.7	21
22	Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology, 2014, 82, 1752-1753.	1.5	20
23	Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience. Journal of Neurology, 2022, 269, 5848-5857.	1.8	17
24	Restless legs syndrome and post polio syndrome: a caseâ^'control study. European Journal of Neurology, 2015, 22, 472-478.	1.7	15
25	Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study). Neurological Sciences, 2020, 41, 487-488.	0.9	14
26	Narrative Medicine to integrate patients', caregivers' and clinicians' migraine experiences: the DRONE multicentre project. Neurological Sciences, 2021, 42, 5277-5288.	0.9	14
27	Subclinical cochlear dysfunction in newly diagnosed relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 33, 55-60.	0.9	13
28	Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case–Control Study. Pharmaceuticals, 2022, 15, 253.	1.7	13
29	Feasibility of automated detection of sleep apnea using implantable pacemakers and defibrillators: a comparison with simultaneous polysomnography recording. Journal of Interventional Cardiac Electrophysiology, 2019, 56, 327-333.	0.6	11
30	Could the New Anti-CGRP Monoclonal Antibodies Be Effective in Migraine Aura? Case Reports and Literature Review. Journal of Clinical Medicine, 2022, 11, 1228.	1.0	11
31	Chronic dopaminergic treatment in restless legs syndrome: does it affect the autonomic nervous system?. Sleep Medicine, 2015, 16, 1071-1076.	0.8	10
32	Oral l-carnitine as treatment for narcolepsy without cataplexy during pregnancy: A case report. Journal of the Neurological Sciences, 2015, 348, 282-283.	0.3	9
33	Symptomatic nonconvulsive status epilepticus erroneously suggestive of sporadic Creutzfeldt–Jakob disease. Journal of the Neurological Sciences, 2015, 348, 274-276.	0.3	9
34	May CSF beta-amyloid and tau proteins levels be influenced by long treatment duration and stable medication in narcolepsy?. Sleep Medicine, 2014, 15, 1424.	0.8	7
35	Treatment with Dimethyl Fumarate Enhances Cholinergic Transmission in Multiple Sclerosis. CNS Drugs, 2019, 33, 1133-1139.	2.7	7
36	Functional Assessment of Outer and Middle Macular Layers in Multiple Sclerosis. Journal of Clinical Medicine, 2020, 9, 3766.	1.0	7

MARIA ALBANESE

#	Article	IF	CITATIONS
37	Morphological Outer Retina Findings in Multiple Sclerosis Patients With or Without Optic Neuritis. Frontiers in Neurology, 2020, 11, 858.	1.1	6
38	Electroencephalography and Dementia: A Literature Review and Future Perspectives. CNS and Neurological Disorders - Drug Targets, 2013, 12, 512-519.	0.8	6
39	Facial diplegia resembling bilateral Ramsay Hunt Syndrome. Journal of the Neurological Sciences, 2017, 376, 109-111.	0.3	5
40	TRPV1 polymorphisms and risk of interferon \hat{l}^2 -induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis. Journal of Neuroimmunology, 2017, 305, 172-174.	1.1	5
41	Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study. PLoS ONE, 2017, 12, e0165415.	1.1	5
42	Abnormal cervical lymph nodes in multiple sclerosis: a preliminary ultrasound study. Radiologia Medica, 2018, 123, 202-208.	4.7	5
43	Distortion Product Otoacoustic Emissions and Their Suppression as Predictors of Peripheral Auditory Damage in Migraine: A Case-Control Study. Journal of Clinical Medicine, 2021, 10, 5007.	1.0	5
44	Pure ictal sensory seizures may represent a clinical manifestation of PLEDs. Epilepsy and Behavior, 2012, 23, 509.	0.9	4
45	Unilateral spatial neglect and alien limb phenomenon may be early features of Creutzfeldt–Jakob disease. Parkinsonism and Related Disorders, 2013, 19, 379-381.	1.1	4
46	Restless legs syndrome and daytime sleepiness are prominent in myotonic dystrophy type 2. Neurology, 2014, 83, 572-573.	1.5	4
47	Epstein–Barr virus neuraxis infection as a trigger for central nervous system demyelinating processes: a case report. Multiple Sclerosis Journal, 2013, 19, 380-381.	1.4	3
48	Effects of epilepsy treatment on sleep architecture and daytime sleepiness: An evidenceâ€based review of objective sleep metrics. Epilepsia, 2014, 55, 777-778.	2.6	3
49	Choriocapillaris Integrity in Relapsed Central Serous Chorioretinopathy in a Patient Treated With Fingolimod for Multiple Sclerosis: New Insights From Optical Coherence Tomography Angiography. Journal of Neuro-Ophthalmology, 2021, 41, e51-e53.	0.4	3
50	Lacosamide as add-on treatment of focal symptomatic epilepsy in a patient with alcoholic liver cirrhosis. Epilepsy & Behavior Case Reports, 2014, 2, 161-163.	1.5	2
51	Multiple sleep latency test may be not sensitive in obstructive sleep apnea with comorbid narcolepsy revealed by low cerebrospinal fluid orexin levels. Sleep Medicine, 2014, 15, 1171.	0.8	2
52	Refractory restless legs syndrome remitting after dual kidney transplantation. Parkinsonism and Related Disorders, 2015, 21, 81-83.	1.1	2
53	Fampridine improves acute optic neuritis contributing to a long-lasting recovery of nerve function. Neurological Sciences, 2021, 42, 4833-4836.	0.9	2
54	Complex Rearrangement of the Entire Retinal Posterior Pole in Patients with Relapsing Remitting Multiple Sclerosis. Journal of Clinical Medicine, 2021, 10, 4693.	1.0	2

#	Article	IF	CITATIONS
55	Spasticity as an ictal pattern due to excitotoxic upper motor neuron damage. Epilepsy and Behavior, 2012, 25, 397-400.	0.9	1
56	Lower instantaneous entropy of heartbeat dynamics during seizures in untreated temporal lobe epilepsy. , 2015, , .		1
57	Fremanezumab in the prevention of high-frequency episodic and chronic migraine: Friend (fremanezumab in real world study), the first Italian multicenter, prospective real-life study. Journal of the Neurological Sciences, 2021, 429, 119272.	0.3	Ο
58	Long-term (>48 weeks) safety and tolerability of erenumab in real-life. Journal of the Neurological Sciences, 2021, 429, 119287.	0.3	0